Effects of Topiramate in the Treatment of Alcohol Dependence

Background: Anticonvulsant drugs have been used in the treatment of alcohol addiction with relatively good results. The purpose of the present study was to evaluate tolerance and safety of topiramate in patients presenting alcohol dependence.

Methods: We studied 24 patients that fulfilled alcohol-dependence criteria (DSM-IV) and presented other psychiatric disorders for which the use of topiramate was indicated. During the 12 weeks of the study, the patients received topiramate (262 mg/day) plus the psychoactive drugs they were taking for the other disorders. Carbohydrate-deficient transferrin (CDT) values and measures of craving and alcohol use were taken every 2 weeks.

Results: Baseline rating of amount and frequency of craving and alcohol use decreased significantly by week 2, and CDT values decreased from week 6. Topiramate was well tolerated, and there were only three dropouts due to adverse events.

Conclusion: Topiramate is safe and well tolerated, and may be beneficial in the treatment of alcohol dependence. A placebo-controlled study would be of interest.

References

• 1 Anton R F, Moak D H, Waid L R,. et al . Naltrexone and Cognitive Behavioral Therapy for the Treatment of Outpatient Alcoholics: Results of a placebo-controlled trial.  Am J Psychiat. 1999;  156 1758-1764
• 2 Berlant J. Topiramate in post-traumatic stress disorder - an open label study -.  Eur Neuropsychopharmacol. 1999;  9 S306-307
• 3 Bonnet U, Banger M, Leweke F M, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentine.  Pharmacopsychiatry. 1999;  32 107-109
• 4 Firsts M B, Spitzer R L, Gibbon M ,. et al .Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition (SCID-IP, Version 2.0). New York, NY; Biometric Research, New York State Psychiatric Institute 1995
• 5 Gidal B E. Topiramate. Drug interactions. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds Antiepileptic drugs 5^th ed. Philadelphia; Lippincott Williams & Wilkins 2002: 735-739
• 6 Herrero A I, Del Olmo N, Gonzalez-Escalada J R, Solís J M. Two new actions of topiramate: Inhibition of depolarizing GABA-A mediated responses and activation of a potassium conductance.  Neuropharmacology. 2002;  42 210-220
• 7 Karam-Hage M, Brower K. Gabapentin treatment for insomnia associated with alcohol dependence.  Am J Psychiat. 2000;  157 151
• 8 Littleton J. Acamprosate in alcohol dependence: how does it work.  Addiction. 1995;  90 1179-1188
• 9 Littrell K H, Petty R G, Hiligoss N M, Peabody C D, Johnson C G. Weight loss with topiramate.  Ann Pharmacother. 2001;  35 1141-1142
• 10 Malcolm R, Myrick H, Brady K T, et al.. Update on anticonvulsants for the treatment of alcohol withdrawal.  Am J Addict. 2001;  10 (Suppl 1) 16-23
• 11 Malhotra S, McElroy S L. Medical management of obesity associated with mental disorders.  J Clin Psychiat. 2002;  63 (Suppl 4) 24-32
• 12 Miller W R. Form 90: A structured Assessment Interview for Drinking and Related Behaviors Test Manual: NIAAA Project Match Monograph Series vol 5. Edited by Mattson ME, Marshall LA, Rockville, Md National Institute on Alcoholism and Alcohol Abuse. 1996
• 13 Mueller T I, Stout R L, Rudden S. et al . A double-blind, placebo-controlled pilot study of carbamazepine for treatment of alcohol dependence.  Alcohol Clin Exp Res. 1997;  21 86-92
• 14 Rogawski M A, Porter R J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds.  Pharmacol Rev. 1990;  42 223-286
• 15 Rubio G, Jiménez-Arriero M A, Ponce G, Palomo T. Naltrexone versus Acamprosate: 1 year follow-up alcohol dependence treatment.  Alcohol Alcoholism. 2001;  36 419-425
• 16 Rubio G, Ponce G, Jiménez-Arriero M A, Palomo T, Ferre F. Effectiveness of topiramate in control of alcohol craving.  Eur Psypharmacol. 2002;  12 (Suppl 2) S63
• 17 Rubio G, Ponce G, Manzanares J. Naltrexone for alcohol dependence (letter).  N Engl J Med. 2002;  346(17) 1329-1330
• 18 Rubio G, Urosa B, Santo-Domingo J. Validación de la Escala de la intensidad de la dependencia alcohólica.  Psiquiatría Biológica. 1998;  (Suppl 1) 44-47
• 19 Sachs G, Gaughan S, Koslow C ,. et al . Topiramate shows efficacy in the treatment of refractory bipolar mood disorder.  Int J Neuropsychopharmacol. 2000;  3 (Suppl 1) S335
• 20 Schiffer W K, Gerasimov M R, Marsteller D A, Geiger J, Barnett C, Alexoff D L, Dewey S L. Topiramate selectively attenuates nicotine-induced increases in monoamine release.  Synapse. 2001;  42 196-198
• 21 Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt L G, Heinz A. Psychopharmacological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence.  Pharmacopsychiatry. 2001;  34 66-72
• 22 Schmidt do Prado-Lima P A, Bacaltchuck J. Topiramate in treatment-resistant depression and binge-eating disorder.  Bipolar Disord. 2002;  4 271-273
• 23 Shank R P, Gardocki J F, Streeter A J, Maryanoff B E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.  Epilepsia. 2000;  41 (Suppl 1) S3-9
• 24 Shapira N A, Goldsmith T D, McElroy S L. Treatment of binge eating disorder with topiramate. XI World Congress of Psychiatry, Hamburg Germany; August 1999
• 25 Swift R M. Medications and alcohol craving.  Alcohol Res Health. 1999;  23 207-213
• 26 Vieta E, Gilabert A, Rodríguez A ,. et al . Topiramate in the adjunctive treatment of refractory bipolar disorder.  Int J Neuropsychopharmacol. 2000;  3 (Suppl 1) S333